Microbiota-Derived Proteins Induce IL-10 Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches using high-dose recombinant human IL-10 for inflammatory and autoimmune diseases are limited by side effects and antibody development, necessitating alternative methods to increase IL-10 levels effectively.
Innovation Solution
Development of isolated proteins or fragments from non-pathogenic microbiota, specifically from the human gastrointestinal tract microbiota, which are capable of inducing or enhancing IL-10 secretion from human cells, including those with specific amino acid sequences and cysteine content, and their corresponding nucleic acids, vectors, and genetically engineered bacteria for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose recombinant human IL-10 is administered to treat inflammatory and autoimmune diseases, then therapeutic effectiveness is improved, but side effects and antibody development occur
Solution Approach 1:
The patent uses microbiota-derived proteins as intermediary substances that indirectly induce IL-10 production through host cell mechanisms rather than administering IL-10 directly. These proteins from non-pathogenic microbiota act as mediators that stimulate the host's own immune cells to produce IL-10, thereby achieving therapeutic effects while avoiding the harmful effects associated with direct high-dose IL-10 administration
Solution Approach 2:
The invention enables the host's own immune system to produce IL-10 in response to microbiota-derived protein stimulation. Instead of relying on external IL-10 administration, the host cells are activated to self-produce the cytokine through recognition and response to the microbiota proteins, creating a self-regulating therapeutic mechanism
2Quantity of substance
If traditional methods such as E. coli lysates or phytohemagglutinin are used to induce IL-10 secretion, then IL-10 levels are increased, but the induction efficiency is limited compared to microbiota-derived proteins
Solution Approach 1:
The patent changes the chemical and structural parameters of the inducing agent by using specific microbiota-derived proteins with particular amino acid sequences and cysteine contents. These parameter changes in the inducing substance result in enhanced IL-10 secretion efficiency compared to traditional inducing agents like E. coli lysates or phytohemagglutin
Data Source
AI summary
The present invention relates to microbiota-derived proteins, which are capable of inducing and/or enhancing secretion of IL-10 from human cells. Accordingly, the present invention provides microbial proteins, and fragments and sequence variants thereof, which stimulate IL-10 release from human immune cells. The present invention also relates to nucleic acids encoding such proteins, cells expressing such proteins, respective pharmaceutical compositions and uses thereof.